EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial

Abstract

Treatment options are limited for patients with extensive stage small cell lung cancer (ES-SCLC) after progression on first line chemo-immunotherapy (CIT). Temozolomide (TEM) is active in ES-SCLC and has been shown to have an immunomodulatory effect for patients with advanced cancers. Immune checkpoint inhibitor (ICI) therapy combined with TEM has demonstrated promising activity among patients in 2nd and 3rd line after CIT (NCT03728361, reported at this meeting). Two different dosing regimens of TEM monotherapy have been explored in ES-SCLC but the objective response rate among patients treated after first line CIT remains unknown.